Bourne RRA, Jonas JB, Bron AM, Cicinelli MV, Das A, Flaxman SR, et al. Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe in 2015: magnitude, temporal trends and projections. Br J Ophthalmol. 2018;102:575–85.

Article  PubMed  Google Scholar 

Owen CG, Jarrar Z, Wormald R, Cook DG, Fletcher AE, Rudnicka AR. The estimated prevalence and incidence of late stage age related macular degeneration in the UK. Br J Ophthalmol. 2012;96:752–6.

Article  PubMed  Google Scholar 

Spaide RF, Jaffe GJ, Sarraf D, Freund KB, Sadda SR, Staurenghi G, et al. Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group. Ophthalmology. 2020;127:616–36.

Article  PubMed  Google Scholar 

Adamis AP, Brittain CJ, Dandekar A, Hopkins JJ. Building on the success of anti-vascular endothelial growth factor therapy: a vision for the next decade. Eye. 2020;34:1966–72.

Article  PubMed  PubMed Central  Google Scholar 

Mehta H, Tufail A, Daien V, Lee AY, Nguyen V, Ozturk M, et al. Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors. Prog Retin Eye Res. 2018;65:127–46.

Article  CAS  PubMed  Google Scholar 

Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729–40.

Article  CAS  PubMed  Google Scholar 

Sahni J, Dugel PU, Patel SS, Chittum ME, Berger B, Del Valle Rubido M, et al. Safety and efficacy of different doses and regimens of faricimab vs ranibizumab in neovascular age-related macular degeneration: the AVENUE Phase 2 randomized clinical trial. JAMA Ophthalmol. 2020;139:955–63.

Article  Google Scholar 

MHRA approves faricimab through international work-sharing initiative - GOV.UK. https://www.gov.uk/government/news/mhra-approves-faricimab-through-international-work-sharing-initiative.

Vabysmo | European Medicines Agency (EMA). https://www.ema.europa.eu/en/medicines/human/EPAR/vabysmo.

Genentech: Press Releases | Friday, Jan 28, 2022. https://www.gene.com/media/press-releases/14943/2022-01-28/fda-approves-genentechs-vabysmo-the-firs?sf159058256=1.

Hussain RM, Neiweem AE, Kansara V, Harris A, Ciulla TA. Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease. Expert Opin Investig Drugs. 2019;28:861–9.

Article  CAS  PubMed  Google Scholar 

Khanani AM, Aziz AA, Khan H, Gupta A, Mojumder O, Saulebayeva A, et al. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study – 6 month results. Eye. 2023;37:3574–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Grimaldi G, Cancian G, Rizzato A, Casanova A, Perruchoud-Ader K, Clerici M, et al. Intravitreal faricimab for neovascular age-related macular degeneration previously treated with traditional anti-VEGF compounds: a real-world prospective study. Graefe’s Arch Clin Exp Ophthalmol. 2024;262:1151–9.

Article  CAS  Google Scholar 

Goodchild C, Bailey C, Soto Hernaez J, Ahmed E, Salvatore S. Real world efficacy and durability of faricimab in patients with neovascular AMD (nAMD) who had sub-optimal response to prior anti-VEGF therapy. Eye. 2024. https://doi.org/10.1038/s41433-024-03218-7.

Cheng AM, Joshi S, Banoub RG, Saddemi J, Chalam KV. Faricimab effectively resolves intraretinal fluid and preserves vision in refractory, recalcitrant, and nonresponsive neovascular age-related macular degeneration. Cureus. 2023;15:4–11.

Google Scholar 

Sim SY, Chalkiadaki E, Koutsocheras G, Nicholson L, Sivaprasad S, Patel PJ, et al. Real-world 1-year outcomes of treatment-intensive neovascular age-related macular degeneration switched to faricimab. Ophthalmol Retina. 2024. https://doi.org/10.1016/j.oret.2024.07.020.

Leung EH, Oh DJ, Alderson SE, Bracy J, McLeod M, Perez LI, et al. Initial real-world experience with faricimab in treatment-resistant neovascular age-related macular degeneration. Clin Ophthalmol. 2023;17:1287–93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hara C, Wakabayashi T, Fukushima Y, Sayanagi K, Kawasaki R, Sato S, et al. Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept. Graefe’s Arch Clin Exp Ophthalmol. 2019;257:2559–69.

Article  CAS  Google Scholar 

Rush RB, Rush SW. Intravitreal faricimab for aflibercept-resistant neovascular age-related macular degeneration. Clin Ophthalmol. 2022;16:4041–6.

Article  PubMed  PubMed Central  Google Scholar 

Stanga PE, Valentín-Bravo FJ, Stanga SEF, Reinstein UI, Pastor-Idoate S, Downes SM. Faricimab in neovascular AMD: first report of real-world outcomes in an independent retina clinic. Eye. 2023;37:3282–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Meer EA, Oh DH, Brodie FL. Time and distance cost of longer acting anti-VEGF therapies for macular degeneration: contributions to drug cost comparisons. Clin Ophthalmol. 2022;16:4273.

Article  PubMed  PubMed Central  Google Scholar 

Palmieri F, Younis S, Bedan Hamoud A, Fabozzi L. Uveitis following intravitreal injections of faricimab: a case report. Ocul Immunol Inflamm. 2024;32:1873–77.

Article  PubMed  Google Scholar 

Thangamathesvaran L, Kong J, Bressler SB, Singh M, Wenick AS, Scott AW, et al. Severe intraocular inflammation following intravitreal faricimab. JAMA Ophthalmol. 2024;142:365–71.

Article  PubMed  Google Scholar